FDA PMA FDA Class 3 Approved (Withdrawn) 🇺🇸 United States

Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)

PMA: P060009 · Decision Aug 25, 2006
Classifications
1
FEI Numbers
27
Registration Numbers
27

Basic Information

Device Name
Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)
Trade Name
AXSYM CORE-M 2.0 AND AXSYM CORE-M 2.0 CONTROLS
PMA Number
P060009
Device Class
FDA Class 3
Product Code
LOM
Generic Name
Test, hepatitis b (b core, be antigen, be antibody, b core igm)
Medical Specialty
Unknown
Advisory Committee
Microbiology
Decision
Approved (Withdrawn)
Decision Code
APWD
Decision Date
August 25, 2006
Date Received
March 10, 2006
Expedited Review
N
Docket Number
07M-0160

Advisory Committee Statement

APPROVAL FOR THE ABBOTT AXSYM CORE-M 2.0 AND AXSYM CORE-M 2.0 CONTROLS. THESE DEVICES ARE INDICATED FOR: THEAXSYM CORE-M 2.0 IS A MICROPARTICLE ENZYME IMMUNOASSAY (MEIA) INTENDED FOR THE IN VITRO QUALITATIVE DETECTION OF IGM ANTIBODY TO HEPATITIS B VIRUS CORE ANTIGEN (IGM ANTI-HBC) IN ADULT AND PEDIATRIC SERUM (INCLUDING SERUM COLLECTED IN SERUM SEPARATOR TUBES) OR PLASMA (COLLECTED IN POTASSIUM EDTA, SODIUM CITRATE, SODIUM HEPARIN, LITHIUM HEPARIN, OR PLASMA SEPARATOR TUBES). THE ASSAY IS USED AS AN AID IN THE DIAGNOSIS OF ACUTE OR RECENT HEPATITIS B VIRUS (HBV) INFECTION IN CONJUNCTION WITH OTHER LABORATORY RESULTS AND CLINICAL INFORMATION.THE AXSYM CORE-M 2.0 CONTROLS ARE USED FOR MONITORING THE PERFORMANCE OF THE AXSYM SYSTEM (REAGENT AND INSTRUMENT) WHEN USED FOR THE QUALITATIVE DETECTION OF IGM ANTIBODY TO HEPATITIS B VIRUS CORE ANTIGEN (IGM ANTI HBC) WHEN USING THE AXSYM CORE-M 2.0 REAGENT PACK. THE PERFORMANCE OF THE AXSYM CORE-M 2.0 CONTROLS HAS NOT BEEN ESTABLISHED WITH ANY OTHER ANTI-HBC ASSAYS.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
LOM Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)